Gelteq Limited Ordinary Shares
GELSHealthcare|Drug Manufacturers - Specialty & Generic|AU
$0.44
-0.02 (-3.42%)
Cash / Share
$0.00
Financials
Financial Snapshot
Market Cap
$4.0M
Enterprise Value
$11.0M
Revenue (TTM)
$280.3K
Net Income (TTM)
-$7.1M
Cash & Investments
$9.3K
Net Cash
-$5.1M
Free Cash Flow (TTM)
-$1.8M
Operating CF (TTM)
-$641.3K
Debt/Equity
0.36
Cash Runway & Burn Rate
Cash on Hand
$9.3K
Quarterly Burn
$160.3K
Monthly Burn
$53.4K
Est. Runway
~0.1 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $319.5K | $181.7K | $162.5K | $399.2K | $24.5K | $344.6K | $9.3K | |
| Operating Cash Flow | $0.00 | $0.00 | $0.00 | -$1.8M | -$1.1M | -$5.5M | -$641.3K | |
| Free Cash Flow | -$354.1K | -$276.9K | -$1.5M | -$1.8M | -$1.2M | -$6.2M | -$1.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$75.9K | -$148.2K | -$642.2K | -$83.9K | |
| Financing Cash Flow | $681.5K | $200.00 | $1.5M | $2.0M | $843.9K | $6.5M | $1.3M |
R&D Spending
R&D (TTM)
$698.9K
R&D Intensity
249.3%
R&D Growth vs Prior
+11.2%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $147.5K | $79.8K | $0.00 | $165.6K | $280.3K | |
| R&D Expense | $342.4K | $277.1K | $529.0K | $665.0K | $276.1K | $628.6K | $698.9K | |
| R&D % of Revenue | — | — | 358.6% | 832.9% | — | 379.5% | 249.3% | |
| SG&A | $230.5K | $463.7K | $1.5M | $1.7M | $1.3M | $2.2M | $3.4M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $147.5K | $79.8K | $0.00 | $165.6K | $280.3K | |
| Cost of Revenue | $0.00 | $0.00 | $94.9K | $48.9K | $0.00 | $0.00 | $115.4K | |
| Gross Profit | $0.00 | $0.00 | $52.7K | $30.9K | $0.00 | $165.6K | $164.9K | |
| R&D | $342.4K | $277.1K | $529.0K | $665.0K | $276.1K | $628.6K | $698.9K | |
| SG&A | $230.5K | $463.7K | $1.5M | $1.7M | $1.3M | $2.2M | $3.4M | |
| Operating Income | $0.00 | -$647.6K | -$3.2M | -$3.1M | -$2.9M | -$5.5M | -$6.4M | |
| Interest Expense | $0.00 | $1.3K | $174.5K | $403.5K | $585.1K | $1.9M | $902.1K | |
| Pretax Income | -$529.6K | -$648.9K | -$3.4M | -$3.5M | -$3.5M | -$6.6M | -$7.1M | |
| Net Income | -$375.6K | -$648.9K | -$3.4M | -$3.5M | -$3.5M | -$6.6M | -$7.1M | |
| EPS (Diluted) | -0.16 | -0.07 | -0.36 | -0.37 | 0.00 | 0.00 | -0.70 | |
| EBITDA | -$527.2K | -$589.7K | -$2.0M | -$1.9M | -$1.8M | -$3.5M | -$5.3M | |
| Shares Out. (M) | 2.35 | 9.44 | 9.44 | 9.44 | 9.44 | 10.03 | 10.48 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $319.5K | $181.7K | $162.5K | $399.2K | $24.5K | $344.6K | $9.3K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $574.5K | $374.9K | $720.1K | $991.0K | $303.2K | $1.5M | $533.1K | |
| Total Assets | $619.1K | $24.2M | $23.4M | $22.5M | $20.8M | $21.5M | $20.1M | |
| Total Current Liabilities | $229.9K | $235.9K | $1.1M | $1.4M | $3.9M | $5.6M | $5.9M | |
| Long-Term Debt | $166.1K | $167.3K | $1.5M | $2.5M | $1.8M | $13.6K | $13.6K | |
| Total Liabilities | $396.0K | $403.2K | $2.6M | $3.8M | $5.6M | $5.7M | $5.9M | |
| Stockholders' Equity | $223.1K | $23.8M | $20.9M | $18.7M | $15.1M | $15.8M | $14.2M | |
| Retained Earnings | -$460.4K | -$1.1M | -$4.5M | -$7.9M | -$11.5M | -$18.1M | -$21.9M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | $0.00 | $0.00 | -$1.8M | -$1.1M | -$5.5M | -$641.3K | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | -$75.9K | -$148.2K | -$642.2K | -$83.9K | |
| Free Cash Flow | -$354.1K | -$276.9K | -$1.5M | -$1.8M | -$1.2M | -$6.2M | -$1.8M | |
| Investing Cash Flow | -$10.0K | $138.9K | $0.00 | -$75.9K | -$148.2K | -$736.8K | -$83.9K | |
| Financing Cash Flow | $681.5K | $200.00 | $1.5M | $2.0M | $843.9K | $6.5M | $1.3M | |
| Issuance of Stock | $300.0K | $0.00 | $0.00 | $1.4M | $0.00 | $7.9M | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $57.9K | $200.00 | $1.5M | $721.2K | $843.9K | $482.8K | $1.7M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $317.4K | -$137.9K | -$19.2K | $236.7K | -$374.7K | $320.1K | -$479.8K |
Dilution Tracker
Shares outstanding grew 327.2% over 5 years — significant dilution
Shares Outstanding
9M
5-Year Share Growth
+327.2%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 2.35 | 9.44 | 9.44 | 9.44 | 9.44 | 10.03 | 10.48 | |
| Change vs Prior % | — | 302.1% | 0.0% | 0.0% | 0.0% | 6.3% | 4.5% | |
| Stock Issuance | $300.0K | $0.00 | $0.00 | $1.4M | $0.00 | $7.9M | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | 35.7% | 38.7% | — | 100.0% | 58.8% | |
| Operating Margin % | — | — | -2164.4% | -3885.3% | — | -3317.7% | -2268.5% | |
| Net Margin % | — | — | -2283.4% | -4391.4% | — | -4011.9% | -2526.9% | |
| EBITDA Margin % | — | — | -1341.1% | -2373.5% | — | -2099.6% | -1901.0% | |
| FCF Margin % | — | — | -1022.1% | -2312.5% | — | -3721.1% | -651.9% | |
| ROE % | -168.4% | -2.7% | -16.2% | -18.8% | -23.5% | -42.0% | -36.1% | |
| ROA % | -60.7% | -2.7% | -14.4% | -15.6% | -17.1% | -30.9% | -26.9% | |
| ROIC % | 0.0% | -2.7% | -14.3% | -14.7% | -15.5% | -27.4% | -25.6% | |
| R&D / Revenue % | — | — | 358.6% | 832.9% | — | 379.5% | 249.3% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | -45.9% | -100.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -41.3% | -100.0% | 0.0% | |
| Operating Income | 0.0% | 0.0% | -393.1% | 2.9% | 5.0% | -86.5% | |
| Net Income | 0.0% | -72.8% | -419.2% | -4.1% | -1.1% | -87.4% | |
| EPS (Diluted) | 0.0% | 57.0% | -423.3% | -2.8% | 100.0% | 0.0% | |
| Operating Cash Flow | 0.0% | 0.0% | 0.0% | 0.0% | 39.5% | -415.8% | |
| Free Cash Flow | 0.0% | 21.8% | -444.5% | -22.4% | 34.0% | -405.8% | |
| R&D Expense | 0.0% | -19.1% | 90.9% | 25.7% | -58.5% | 127.7% | |
| SG&A Expense | 0.0% | 101.2% | 233.5% | 9.8% | -25.4% | 75.5% | |
| Total Assets | 0.0% | 3811.9% | -3.3% | -3.9% | -7.7% | 3.5% | |
| Book Value / Share | 0.0% | 2555.4% | -12.4% | -10.5% | -19.0% | -1.6% | |
| Debt | 0.0% | 0.8% | 778.6% | 64.6% | 54.4% | 9.7% | |
| Diluted Shares | 0.0% | 302.1% | 0.0% | 0.0% | 0.0% | 6.3% |
Valuation
P/E (TTM)At Loss
P/S25.54
10Y Low / Med / High159.13 / 272.41 / 521.54
P/B0.47
10Y Low / Med / High1.55 / 2.23 / 44.81
EV/EBITDAAt Loss
EV/Revenue47.79
10Y Low / Med / High182.51 / 281.56 / 547.71
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.00
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -26.62 | -56.96 | -11.83 | -11.92 | -11.75 | -3.97 | -1.20 | |
| P/S Ratio | 0.00 | 0.00 | 272.41 | 521.54 | 0.00 | 159.13 | 25.54 | |
| P/B Ratio | 44.81 | 1.55 | 1.93 | 2.23 | 2.76 | 1.67 | 0.47 | |
| EV/EBITDA | -18.68 | -62.70 | -21.00 | -23.08 | -25.30 | -8.69 | -2.66 | |
| EV/Revenue | 0.00 | 0.00 | 281.56 | 547.71 | 0.00 | 182.51 | 47.79 |
Analyst Estimates & Quality
Altman Z-Score
-2.31
Distress
Piotroski F-Score
3
Weak